Zsa Zsa Weerts

Chapter 3 64 References 1. El-Salhy M. Irritable bowel syndrome: diagnosis and pathogenesis. World J Gastroenterol. 2012;18:5151-5163. 2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10:712-721 e714. 3. Van den Houte K, Carbone F, Pannemans J, et al. Prevalence and impact of self-reported irritable bowel symptoms in the general population. United European Gastroenterol J. 2018;7:307-315. 4. Jossan N, Simren M, Sperber AD, et al. Health care utilization for Rome IV irritable bowel syndrome; a three-country survey in the general population. Gastroenterology. 2017;152:S68. 5. Camilleri M. Peripheral mechanisms in irritable bowel syndrome, N Engl J Med. 2012;367:1626-1635. 6. Holtmann GJ, Ford AC, Talley, NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016; 1:133- 146. 7. Ballou S, Keefer L. The impact of irritable bowel syndrome on daily functioning: Characterizing and understanding daily consequences of IBS. Neurogastroenterol Motil. 2017;29. 8. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. 2000;119:654-660. 9. Palsson OS, Baggish J, Whitehead WE. Episodic nature of symptoms in irritable bowel syndrome. Am J Gastroenterol. 2014:109:1450-1460. 10. Drossman DA, Morris CB, Hu Y, et al. A prospective assessment of bowel habit in irritable bowel syndrome in women: defining an alternator. Gastroenterology. 2005;128:580-589. 11. Garrigues V, Mearin F, Badia X, et al. Change over time of bowel habit in irritable bowel syndrome: a prospective, observational, 1- year follow-up study (RITMO study). Aliment Pharmacol Ther. 2007:25:323-332. 12. Williams RE, Black CL, Kim HY, et al. Stability of irritable bowel syndrome using a Rome II- based classification. Aliment Pharmacol Ther. 2006:23:197-205. 13. Spiegel B, Harris L, Lucak S, et al. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. Am J Gastroenterol. 2009;104: 1984-1991. 14. Corsetti M, Whorwell P. The global impact of IBS: time to think about IBS-specific models of care?, Therap Adv Gastroenterol. 2017;10:727-736. 15. Mujagic Z, Jonkers D, Ludidi S, et al. Biomarkers for visceral hypersensitivity in patients with irritable bowel syndrome. Neurogastroenterol Motility. 2017;29(12). 16. Ludidi S, Mujagic Z, Jonkers D, et al. Markers for visceral hypersensitivity in patients with irritable bowel syndrome, Neurogastroenterol Motil. 2014;26:1104-1111. 17. Thijssen AY, Mujagic Z, Jonkers DM, et al. Alterations in serotonin metabolism in the irritable bowel syndrome. Aliment Pharmacol Ther. 2016:43:272-282. 18. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. 19. Svedlund J, Sjodin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33: 129-134. 20. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361-370. 21. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002;52:69-77. 22. McHorney CA, Ware JE, Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF- 36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247-263. 23. Farivar SS, Cunningham WE, Hays RD. Correlated physical and mental health summary scores for the SF-36 and SF-12 Health Survey, V.I. Health Qual Life Outcomes. 2007;5:54.